Forest Laboratories, Inc. Finalizes Previously Disclosed Settlement of U.S. Government Investigations

Forest Laboratories, Inc.Forest Laboratories, Inc. (NYSE: FRX) has finalized a previously reported agreement-in-principle to resolve all aspects of the investigations led by the United States Department of Justice (DOJ) and the United States Attorney's Office for the District of Massachusetts that began in January 2004 relating to past marketing, sales, and other activities in connection with Celexa(R), Lexapro(R), and a formulation of Levothroid(R) that Forest ceased distributing in 2003. Forest previously disclosed reserves totaling $313 million plus interest in connection with these investigations. All of the payments described below are covered by such reserves and no additional charge to the company's earnings will be recorded in connection with the final settlement.

As one part of the resolution, Forest Pharmaceuticals, Inc., a wholly owned subsidiary of Forest Laboratories, Inc., has agreed pursuant to a plea agreement to plead guilty to a single felony charge of obstructing an agency proceeding, which relates to misstatements by certain Forest plant employees to FDA inspectors during a November 2003 plant inspection. In addition, Forest Pharmaceuticals, Inc. has agreed to plead guilty to two strict liability, no-intent misdemeanor violations of the Food, Drug and Cosmetic Act: the first misdemeanor involves the distribution of an unapproved new drug, Levothroid(R), between August 2001 and August 2003 (following an FDA determination that the levothyroxine supplement drug class required NDA registration); and the second misdemeanor involves the off-label promotion of Celexa(R) as a treatment for pediatric patients (for which Celexa(R) had not been approved) between 1998 and 2002. Neither misdemeanor charge includes as an element false or deceptive conduct. As part of the resolution of the criminal investigation, Forest has agreed to pay to the United States a fine of approximately $150 million and a forfeiture payment of $14 million.

In addition, as previously disclosed, Forest has agreed to resolve civil claims asserted by DOJ under the False Claims Act and in qui tam lawsuits relating to allegations concerning the distribution of Levothroid(R) without an NDA between August 2001 and August 2003, and off-label promotion of Celexa(R) and Lexapro(R) for pediatric use between 1998 and 2005 (prior to the FDA approval of Lexapro for the treatment of major depressive disorder in adolescents, in March 2009). The resolution calls for Forest to make payments to the federal government and state Medicaid programs totaling approximately $149 million plus interest. Forest expressly denies the allegations made in connection with the civil claims being settled. The civil settlement will resolve the allegations contained in the civil complaint filed by the United States in February 2009, as well as the complaints filed by qui tam relators, and those complaints all will be dismissed.

Also as part of the settlement, Forest has entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services. The CIA requires Forest to maintain its current compliance program and to undertake a set of defined corporate integrity obligations for a period of five years. The CIA also provides for an independent third-party review organization to assess and report on Forest's compliance program.

"We are pleased to bring closure to this long-running investigation. We remain dedicated to ensuring that we operate in full compliance with all laws and regulations, and that our employees uphold the highest principles of integrity, honesty, and ethics. We have continued to enhance our compliance program since the events at issue in this investigation which occurred a number of years ago. We will continue to fulfill our corporate mission of developing and delivering pharmaceutical products for the treatment of a variety of serious and life-threatening conditions, and to meet our responsibilities to the patients and healthcare professionals we serve," said Howard Solomon, Chairman and Chief Executive Officer of Forest.

The settlement and guilty pleas are subject to approval by the U.S. District Court for the District of Massachusetts.

About Forest Laboratories
Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more about Forest Laboratories, visit http://www.FRX.com.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...